Thymogen
Also known as: Thymagen, EW, Glu-Trp, L-Glu-L-Trp, Oglufanide, Timogen, IM-862
EW Dipeptide | Thymus Immune Bioregulator
Overview
Thymogen (EW dipeptide) is a Khavinson bioregulator consisting of glutamic acid and tryptophan, originally isolated from calf thymus extracts (Thymalin) in the late 1980s. Developed by Professor Vladimir Khavinson, it has been registered in Russia since 1990 in multiple forms including injectable solution, nasal spray, and topical cream. Thymogen modulates both humoral and cellular immunity, activates T-cell differentiation, and has demonstrated geroprotective (anti-aging) and antitumor activities in research studies.
Key benefits
- Modulates humoral and cellular immunity
- Activates T-cell differentiation
- Normalizes T-lymphocyte populations (CD3+, CD4+, CD8+)
- Stimulates immunoglobulin production
- Enhances regeneration and cellular metabolism
- Demonstrated geroprotective (anti-aging) activity
- Antitumor activity in research models
- Registered pharmaceutical in Russia
- Multiple delivery forms available
Mechanism of action
Thymogen works through multiple immunomodulatory mechanisms: (1) activates T-cell differentiation and T-cell recognition of peptide-MHC complexes, (2) induces changes in intracellular cyclic nucleotide composition, (3) activates neutrophilic chemotaxis and phagocytosis, (4) normalizes T-lymphocyte concentrations and ratios (CD3+, CD4+, CD8+), (5) stimulates production of immunoglobulins (IgA, IgG, IgE, IgM), and (6) enhances lymphocyte differentiation receptor expression. Research suggests Thymogen may interact specifically with the AACG DNA sequence, affecting gene expression. The peptide is rapidly distributed to thymus, lymph nodes, liver, adrenals, and kidneys.
Molecular data
- Type
- Dipeptide bioregulator
- Half-life
- Not established
Sequence
Glu-Trp (EW)
Indications
What the research community uses this compound for, with self-reported effectiveness.
Immune Support
Anti-Aging Research
Clinical Research Areas
Dosing protocols
Common protocols by delivery method. Adjust the curve below to model accumulation in your own cycle.
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | 10-20 mg | Daily for 10-20 days | — |
| — | 20 mg | 2-3 cycles per year | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | As per product directions | Daily during cycle | — |
Delivery method
| Protocol | Dose | Frequency | Duration |
|---|---|---|---|
| — | Apply thin layer | As directed | — |
Safety
Reported adverse effects, contraindications, and what to monitor on cycle.
Common side effects
- Generally well-tolerated
- Injection site reactions (mild)
- Minimal side effects reported in clinical use
Rare side effects
- Allergic reactions (rare)
Contraindications
- Active autoimmune diseases (use with caution)
- Organ transplant recipients on immunosuppression
- Known hypersensitivity to component amino acids
- Pregnancy or breastfeeding
Monitoring
- Immune function if testing available
- T-cell subsets for research protocols
- General well-being
References
Primary literature and clinical-trial data informing this entry.